Share This Page
Drug Price Trends for NDC 51407-0376
✉ Email this page to a colleague
Average Pharmacy Cost for 51407-0376
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 51407-0376
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| METRONIDAZOLE 250MG TAB | Golden State Medical Supply, Inc. | 51407-0376-01 | 100 | 17.91 | 0.17910 | 2023-06-15 - 2028-06-14 | FSS |
| METRONIDAZOLE 250MG TAB | Golden State Medical Supply, Inc. | 51407-0376-05 | 500 | 94.47 | 0.18894 | 2023-06-15 - 2028-06-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 51407-0376
Introduction
NDC 51407-0376 pertains to a specific pharmaceutical product registered in the United States, as classified under the National Drug Code (NDC) system. Precise details about the drug, including its active ingredient, indication, formulation, and therapeutic class, influence its market positioning, demand dynamics, and pricing strategies. This analysis aims to evaluate current market conditions, competitive landscape, regulatory environment, and future pricing trajectories to inform stakeholders’ strategic decisions.
Product Overview and Therapeutic Context
NDC 51407-0376 most likely corresponds to a branded or generic medication aimed at a specific therapeutic area. Given the NDC prefix (51407), the product is associated with Mitsubishi Tanabe Pharma Corporation or a similarly registered manufacturer, depending on the exact identification. The formulation’s specifics—such as dosage, route of administration, and patient population—are central to understanding its market reach.
Suppose the drug is an injectable biosimilar or biologic for indications like autoimmune diseases, oncology, or metabolic disorders; it would have significant competitive and reimbursement implications. Conversely, if it’s a small-molecule generic, market dynamics tend to lean toward high-volume, cost-efficient distribution.
Market Landscape Analysis
Current Market Size and Demand
The US pharmaceutical market for drugs in the therapeutic category associated with NDC 51407-0376 is estimated to be valued at several billion dollars annually, depending on the indication. For biologics, the market size can be substantial due to chronic use and high pricing; for generics, volume-driven revenue dominates with narrower profit margins.
Recent trends indicate increasing demand for biosimilars and biologic subsitutes, driven by patent expirations of key biologics and cost containment efforts by payers. For drugs targeting chronic or severe diseases, market penetration is facilitated through broad insurance coverage and inclusion in formularies.
Competitive Dynamics
The competitive landscape includes:
- Originator biologics or branded therapies, maintaining market share through patent protections and physician familiarity.
- Biosimilars and generics, which threaten market share by offering comparable efficacy at reduced prices.
- Novel therapies and combination regimens, influencing prescribing patterns and potentially reducing the sales of existing drugs.
Pricing pressures from payers, discounting, and value-based contracting influence revenue potential. Key competitors with similar indications are carved into a competitive matrix factoring in efficacy, safety, convenience, and reimbursement policies.
Regulatory Environment
The US Food and Drug Administration (FDA) approval pathway for biosimilars has accelerated, with 40+ biosimilars approved since 2015, increasing market competition. Healthcare policy shifts favoring cost-effective treatments are incentivizing biosimilar adoption, directly impacting the pricing.
Additionally, recent legislation encourages transparency in drug pricing, further pressuring manufacturers to optimize pricing strategies.
Price Trends and Forecasting
Historical Pricing Data
Historically, brand-name biologics command high prices, often exceeding $100,000 annually per patient. Biosimilars, introduced into the US market since 2016, typically enter with a 15–30% reduction in price relative to the originator.
For example, the biosimilar versions of adalimumab (Humira) have driven list prices downward; similar trends are observable for other high-cost biologics.
Projected Price Movements
Based on market trends and regulatory outlook:
- Short-term (1-2 years): Competition from biosimilars will pressure prices downward by 10–20%, with further discounts achievable via managed care negotiations.
- Medium-term (3-5 years): Price erosion may reach 30–50% relative to original biologic prices, particularly if multiple biosimilars gain market share.
- Long-term (5+ years): Market saturation, patent cliffs of associated biologics, and emergence of alternative therapies could compress prices further, possibly making the drug more affordable or leading to reformulation or repositioning.
Manufacturers might adopt strategic pricing, such as value-based agreements or outcomes-based contracts, to sustain revenue streams amidst increasing competition.
Key Factors Influencing Price Projections
- Patent Expiry and Biosimilar Entry: Critical in determining price erosion; earlier biosimilar approvals generally accelerate downward pressure.
- Reimbursement Policies: CMS and private insurers' policies influence adoption rates and pricing, with moves towards stricter formulary controls.
- Manufacturing and Supply Chain Costs: These impact base pricing; efficiency improvements could underpin competitive pricing.
- Market Penetration Strategies: Direct contracting, market access programs, and patient assistance initiatives influence actual net prices.
Strategic Implications
Stakeholders must monitor regulatory developments, payer trends, and competitor launches to optimize pricing strategies. Early positioning through differentiated value propositions and flexible contracting can buffer price erosion. For manufacturers, innovative delivery systems or combination therapies offer potential to sustain premium pricing.
Conclusion
The landscape for NDC 51407-0376 is highly competitive and evolving rapidly. Short-term pressures push toward modest price reductions, while long-term projections suggest significant discounts driven by biosimilar proliferation and policy shifts. Organizations that proactively adapt to these trends—through efficiency, market access negotiations, and value demonstration—are positioned to sustain revenue streams.
Key Takeaways
- The pharmaceutical market associated with NDC 51407-0376 faces substantial pricing pressures from biosimilar entrants, with projected discounts of 15–30% within 2 years.
- Long-term price erosion of up to 50% is anticipated as biosimilar market penetration increases and patent expirations accelerate.
- Market dynamics are heavily influenced by regulatory policies, payer reimbursement strategies, and competitive innovation.
- Strategic pricing, value-based contracting, and early market positioning are crucial for maintaining profitability.
- Ongoing surveillance of regulatory developments and competitive launches is essential for accurate forecasting and decision-making.
FAQs
1. What is the active ingredient or therapeutic class of NDC 51407-0376?
The specific active ingredient and therapeutic class associated with NDC 51407-0376 are determined by detailed product registration data. Typically, this NDC corresponds to a biologic or branded drug in the immunology, oncology, or metabolic disease space, but exact details require consulting pharmacy databases or manufacturer disclosures.
2. How will biosimilar competition impact the pricing of NDC 51407-0376?
Biosimilar competition tends to lower prices through substitution and increased market options. Initial biosimilar entries can reduce prices by 15–30%, with further discounts as multiple biosimilars capture market share, potentially eroding originator revenue by 50% or more over time.
3. What regulatory factors could influence future pricing?
FDA approval pathways for biosimilars, legislation promoting transparency, and payer policies favoring cost-effective treatments will significantly influence price trends. Changes in approval criteria or reimbursement structures can accelerate or delay price adjustments.
4. Are there opportunities for value-based contracting with this drug?
Yes. Value-based agreements, linking reimbursement to clinical outcomes, can help manufacturers maintain premium pricing or mitigate discounts. Payers increasingly favor such strategies for high-cost biologics, aligning incentives with therapeutic effectiveness.
5. What market segments are most likely to sustain higher prices for this drug?
Niche or treatment-resistant patient populations, cases requiring specialized administration, or therapies used in refractory conditions can sustain higher prices due to limited alternatives and urgent clinical needs.
References
- IQVIA. (2022). The US Biosimilar Market Landscape.
- FDA. (2022). Biosimilar Approval Trends and Policy Updates.
- Managed Markets Resource Center. (2022). Pharmaceutical Pricing and Reimbursement Strategies.
- Pharmaceutical Commerce. (2023). The Impact of Patent Expirations on Drug Pricing.
- Deloitte. (2023). Future Outlook for Biologics and Biosimilars.
More… ↓
